Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1b LY2157299 plus gemcitabine in unresectable pancreatic cancer
jRCT2080222513Phase 1
- Sponsor
- Eli Lilly and Company
- Start
- Jun 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, single-arm trial of galunisertib in pancreatic adenocarcinoma (PDAC), sponsored by Eli Lilly and Company.
02
Drugs
galunisertib
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on jRCT2080222513.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080222513.